Merck KGaA Acquires Rights For Colorectal Cancer Therapy UFT From Taiho
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany-based Merck says it has not decided whether it will seek FDA approval for the uracil/tegafur combination; FDA deemed UFT “not approvable” for advanced colorectal cancer in 2001, when Bristol held rights to the agent.
You may also be interested in...
Sanofi-Aventis To Assume Development Of Phase III Anticancer Agent S-1
Sanofi will pay Taiho Pharmaceutical up to $360 mil. for S-1, which combines two enzyme inhibitors with the 5-FU prodrug tegafur.
Sanofi-Aventis To Assume Development Of Phase III Anticancer Agent S-1
Sanofi will pay Taiho Pharmaceutical up to $360 mil. for S-1, which combines two enzyme inhibitors with the 5-FU prodrug tegafur.
Oncology Drug Combos Are Held Back By IP Issues, Not FDA, Pazdur Tells ASCO
Development of oncology drug combination products is more often held back by intellectual property issues than by FDA regulatory requirements, Oncologic Drug Products Division Director Richard Pazdur said during the American Society of Clinical Oncology meeting in New Orleans June 5